CORDIS
EU research results

CORDIS

English EN

Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies

Project information

Grant agreement ID: 853995

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2024

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 31 110 000

  • EU contribution

    € 15 500 000

Coordinated by:

HUMANITAS UNIVERSITY

Italy

Project description

English EN

Novel diagnostics and monitoring approach for immune-mediated diseases

Immune-mediated inflammatory diseases (IMID) include conditions with different aetiologies, characterised by common inflammatory pathways leading to inflammation and triggered by a dysregulation of the normal immune response. IMIDs are heterogeneous with regard to disease outcome and response to targeted therapies; predictive biomarkers are important for a precision medicine approach. Through the EU-funded ImmUniverse project, a transdisciplinary international consortium studies the role of crosstalk between tissue micro-environment and immune cells in disease progression and response to therapy of two IMIDs: ulcerative colitis and atopic dermatitis. The project will bring IMID diagnostics and treatment response monitoring to a new level by implementing non-invasive liquid-biopsy methodology combined with circulating biomarker assays.

Coordinator

HUMANITAS UNIVERSITY

Address

Via Rita Levi Montalcini Snc
20090 Pieve Emanuele

Italy

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 970 093,75

Participants (25)

AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH

Austria

EU Contribution

€ 2 133 236,25

ISTITUTO SUPERIORE DI SANITA

Italy

EU Contribution

€ 504 988,75

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

Germany

EU Contribution

€ 2 613 900

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 659 793,75

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Netherlands

EU Contribution

€ 564 047,50

VIB VZW

Belgium

EU Contribution

€ 652 500

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 740 000

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 492 475

AARHUS UNIVERSITET

Denmark

EU Contribution

€ 199 847,50

AARHUS UNIVERSITETSHOSPITAL

Denmark

EU Contribution

€ 355 596,25

UNIVERSITE DU LUXEMBOURG

Luxembourg

EU Contribution

€ 687 000

JOANNEUM RESEARCH FORSCHUNGSGESELLSCHAFT MBH

Austria

EU Contribution

€ 834 408,75

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 1 248 421,25

CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY

France

EU Contribution

€ 340 783,75

INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA

Luxembourg

EU Contribution

€ 402 501,25

FORUM EUROPEEN DES PATIENTS (FPE)

Luxembourg

EU Contribution

€ 11 781,25

EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING

Belgium

EU Contribution

€ 50 250

EUROPEAN FEDERATION OF CROHN'S AND ULCERATIVE COLITIS ASSOCIATIONS

Belgium

EU Contribution

€ 50 312,50

EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH

Germany

EU Contribution

€ 626 062,50

SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO S ANNA

Italy

EU Contribution

€ 362 000

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

Eli Lilly and Company Limited

United Kingdom

NOVARTIS PHARMA AG

Switzerland

PFIZER LIMITED

United Kingdom

Project information

Grant agreement ID: 853995

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2024

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 31 110 000

  • EU contribution

    € 15 500 000

Coordinated by:

HUMANITAS UNIVERSITY

Italy